Last updated: February 19, 2026
This report analyzes the patent litigation between UCB, Inc. and Sunshine Lake Pharma Co., Ltd. concerning UCB's blockbuster epilepsy drug, Vimpat (lacosamide). The core of the dispute involves allegations of patent infringement of UCB's U.S. Patent No. 7,169,792. Sunshine Lake Pharma seeks to market a generic version of lacosamide, triggering UCB's legal challenge. The case is proceeding in the United States District Court for the District of Delaware.
What is the Scope of the Litigation?
The litigation centers on Sunshine Lake Pharma's submission of an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for its proposed generic lacosamide product. UCB alleges that this submission constitutes infringement of U.S. Patent No. 7,169,792. The patent covers an enantiomerically pure form of lacosamide.
- Plaintiff: UCB, Inc.
- Defendant: Sunshine Lake Pharma Co., Ltd.
- District Court: United States District Court for the District of Delaware
- Case Number: 1:20-cv-01343
- Asserted Patent: U.S. Patent No. 7,169,792 ("the '792 patent")
- Drug at Issue: Lacosamide (brand name Vimpat)
- Infringement Claim: Willful infringement of the '792 patent.
What are the Key Legal Arguments?
UCB asserts that Sunshine Lake Pharma's proposed generic drug infringes the '792 patent. Sunshine Lake Pharma, in turn, has sought to invalidate UCB's patent.
What are UCB's Claims?
UCB's primary claim is that Sunshine Lake Pharma's ANDA submission for generic lacosamide infringes the '792 patent. The '792 patent claims:
"1. A substantially enantiomerically pure compound of the formula (R)-2-acetamido-N-benzyl-3-methoxypropionamide, or a pharmaceutically acceptable salt thereof."
UCB argues that Sunshine Lake Pharma's proposed generic product, which is lacosamide, falls within the scope of this claim. UCB also alleges that Sunshine Lake Pharma's actions constitute willful infringement. This suggests UCB believes Sunshine Lake Pharma was aware of the patent and proceeded with its ANDA filing despite this knowledge.
What are Sunshine Lake Pharma's Defenses?
Sunshine Lake Pharma's primary defense strategy in such cases typically involves challenging the validity of the asserted patent. Common invalidity arguments include:
- Anticipation: The invention was already known or described in prior art.
- Obviousness: The invention would have been obvious to a person skilled in the art at the time of the invention.
- Lack of Enablement/Written Description: The patent does not adequately describe the invention or how to make and use it.
While specific details of Sunshine Lake Pharma's defenses were not immediately available in the initial filings, patent invalidity is a standard defense in Hatch-Waxman litigation.
What is the Status of the Litigation?
The litigation is in its early to mid-stages within the District of Delaware. Key procedural steps have occurred, including the filing of the complaint and the defendant's answer and counterclaims.
- Complaint Filed: UCB filed its complaint on July 10, 2020.
- ANDA Submission: Sunshine Lake Pharma submitted its ANDA on or about June 5, 2020.
- Answer and Counterclaims Filed: Sunshine Lake Pharma filed its answer and counterclaims on August 24, 2020, asserting non-infringement and invalidity of the '792 patent.
- Markman Hearing: A Markman hearing, which determines the construction of patent claims, is a critical step in patent litigation. Dates for such hearings are typically set by the court as the case progresses.
- Discovery: Parties engage in extensive discovery, exchanging documents, interrogatories, and taking depositions.
What is the Key Patent at Issue?
U.S. Patent No. 7,169,792, assigned to UCB, Inc., is central to this dispute. The patent was issued on February 22, 2005. It claims a specific enantiomerically pure form of lacosamide.
- Patent Title: Substantially Enantiomerically Pure 2-acetamido-N-benzyl-3-methoxypropionamide
- Inventors: H. L. Van Tilburg, M. E. Stienstra, and M. J. Meert
- Assignee: UCB, Inc.
- Issue Date: February 22, 2005
- Expiration Date: The patent's term is calculated based on its issue date and filing date, factoring in potential patent term extensions. For a patent issued in 2005, its base term would expire in 2022, not accounting for any extensions. However, Hatch-Waxman litigation typically occurs when a generic company files an ANDA, seeking approval before the patent expires or during the patent term.
The claims of the '792 patent define the specific chemical structure of lacosamide that UCB is protecting. The patent's validity and the scope of its claims are paramount to UCB's infringement allegations.
What are the Potential Outcomes?
The litigation can result in several outcomes, each with significant implications for UCB and Sunshine Lake Pharma, as well as the market for lacosamide.
- Injunction: If UCB prevails and its patent is found valid and infringed, the court may issue an injunction preventing Sunshine Lake Pharma from marketing its generic lacosamide product for the remaining life of the patent, including any extensions.
- Invalidation of Patent: If Sunshine Lake Pharma successfully proves the '792 patent is invalid, UCB would lose its exclusivity, and Sunshine Lake Pharma could seek FDA approval for its generic product.
- Settlement: The parties may reach a settlement agreement at any stage of the litigation. Settlements in Hatch-Waxman cases often involve a licensing agreement, allowing the generic company to launch its product at a predetermined date, often before the patent expires but after a negotiated period.
- Non-Infringement Finding: The court could find that Sunshine Lake Pharma's product does not infringe the claims of the '792 patent, even if the patent is valid.
What is the Market Impact of Lacosamide (Vimpat)?
Lacosamide, marketed as Vimpat by UCB, is a significant pharmaceutical product used for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures in epilepsy patients. Its market performance is a key consideration for both parties involved in the litigation.
- Therapeutic Area: Epilepsy, Anticonvulsant
- Key Indications:
- Adjunctive therapy for partial-onset seizures in patients 4 years of age and older.
- Monotherapy for partial-onset seizures in patients 16 years of age and older.
- Adjunctive therapy for primary generalized tonic-clonic seizures in patients 4 years of age and older.
- Sales Performance: Vimpat has been a consistent top-seller for UCB. Global net sales for Vimpat were approximately €1.6 billion in 2021 and €1.7 billion in 2022, demonstrating its significant market presence and revenue generation for UCB. [1]
- Generic Competition Risk: The advent of generic competition for a drug of Vimpat's sales volume can lead to substantial price erosion and market share loss for the innovator drug. The success of a generic lacosamide product would directly impact UCB's revenue streams.
What are the Key Takeaways?
The litigation between UCB, Inc. and Sunshine Lake Pharma Co., Ltd. involves UCB's attempt to block generic entry of lacosamide by asserting U.S. Patent No. 7,169,792. Sunshine Lake Pharma is challenging the validity of this patent. The outcome will determine market access for generic lacosamide and significantly impact UCB's revenue from Vimpat, a drug with over €1.7 billion in annual sales. The case hinges on patent claim construction, validity, and infringement analysis.
Frequently Asked Questions
What is the specific claim of U.S. Patent No. 7,169,792 that UCB asserts is being infringed?
UCB asserts that Sunshine Lake Pharma's proposed generic lacosamide infringes Claim 1 of U.S. Patent No. 7,169,792, which covers "A substantially enantiomerically pure compound of the formula (R)-2-acetamido-N-benzyl-3-methoxypropionamide, or a pharmaceutically acceptable salt thereof."
On what date was U.S. Patent No. 7,169,792 issued?
U.S. Patent No. 7,169,792 was issued on February 22, 2005.
What is Sunshine Lake Pharma's primary strategy in defending against UCB's patent infringement claims?
Sunshine Lake Pharma's primary defense strategy is to challenge the validity of UCB's asserted patent, U.S. Patent No. 7,169,792, arguing that it is invalid on grounds such as anticipation or obviousness.
What is the approximate annual revenue generated by UCB's drug Vimpat (lacosamide)?
Global net sales for Vimpat were approximately €1.7 billion in 2022, indicating its substantial market value.
In which U.S. District Court is the litigation filed?
The litigation between UCB, Inc. and Sunshine Lake Pharma Co., Ltd. is filed in the United States District Court for the District of Delaware.
Citations
[1] UCB Annual Report 2022. (n.d.). Retrieved from https://www.ucb.com/-/media/global/documents/investors/ucb-annual-report-2022.pdf
